@admin / longevity-researchmission

Longevity Research

Succeeded
Elapsed
793.8s
Cost
Free
Tokens
0
0 in · 0 out
Events
28
click to inspect
live output
Starting mission longevity-research…
==> Longevity-research mission tick starting
==> Goal: Anchor the first human-validated causal relation in the mTORC1–autophagy–inflammaging axis by pursuing a dual-track stra
==> Swarm tick starting. KB: {'entities': 151, 'relations': 0}
── Phase 1: Director
1. Trans-ethnic fine-mapping of the *RPTOR* locus and rare protein-truncating variant drug-target Mendelian Randomization against circulating IL-6 and hs-CRP, integrating European and Ea
Focus: FOCUS AREAS:
── Phase 2: Scouts
[pubmed] fetched 0 items
[pubmed] esearch error: <urlopen error [Errno -3] Temporary failure in name resolution>
[opentargets] fetched 0 items
[opentargets] error: HTTP Error 400: Bad Request
[clinicaltrials] fetched 0 items
[europepmc] fetched 60 items
[medrxiv] fetched 30 items
[biorxiv] fetched 30 items
Items: 120
── Phase 3: Synthesizer
── Phase 4: Critic
── Phase 5: Curator
Findings: 0, Hypotheses: 3
── Phase 6: Reporter
── Phase 7: Director-meta
==> Tick complete. Findings: 0, Hypotheses: 3
==> Tick complete.
Outputs
{
  "result": " This tick, the Gonka Labs swarm zeroed in on a single, high-leverage causal chain: whether mTORC1 inhibition suppresses inflammaging markers—specifically IL-6 and high-sensitivity CRP—through an autophagy-dependent mechanism. Because our knowledge base currently holds 153 relevant entities but zero verified relations for this axis, the team prioritized foundational validation over expansion. Rather than chasing organismal longevity outcomes or broad cytokine panels, we designed a tightly scoped, three-pronged interrogation: trans-ethnic Mendelian Randomization (MR) of the *RPTOR* locus across European and East Asian biobanks; orthogonal cellular perturbation in iPSC-derived macrophages using *RPTOR* CRISPRi and everolimus titration; and multivariable MR to isolate mTORC1 signaling from the closely related mTORC2 and IGF-1 pathways.\n\nThe central hypothesis under scrutiny is that dampening mTORC1—not merely mTOR broadly—relieves suppression of the transcription factors TFEB and TFE3, driving their nuclear translocation and initiating autophagy. In turn, this autophagic flux should attenuate NF-κB p65 phosphorylation in macrophages, thereby reducing secretion of IL-6 and hs-CRP. To test whether this anti-inflammatory effect is truly autophagy-dependent rather than a generic consequence of mTOR suppression, the planned experiments include an *ATG7* knockout condition. If IL-6 secretion persists when autophagy is genetically disabled, the proposed mechanistic link collapses. This is the most interesting aspect of the current framework: it explicitly demands pathway specificity and mechanistic mediation, not just correlation.\n\nIt is critical to state plainly that this tick produced zero new empirical findings. No human genetic instruments were validated, no macrophages were perturbed, and no causal edges were added to the knowledge graph. The evidence base therefore remains at the level of existing published literature scanned by our AI systems—largely theoretical and observational—with no fresh in vitro, animal, or clinical data generated herein. The three updated hypotheses reflect refined priors about confounding structures (notably LD-confounded *RPTOR* instruments and mTORC2/IGF-1 pleiotropy) rather than confirmed biological facts. Consequently, confidence in the mTORC1–autophagy–inflammaging axis remains provisional and low within our specific framework, even though the broader geroscience literature supports the general plausibility of mTOR inhibition as a modulator of immune metabolism.\n\nThe immediate agenda for the next tick is to convert this scaffolding into anchored relations. First, the swarm must resolve whether rare protein-truncating variants in *RPTOR* across diverse ancestries yield clean, LD-independent genetic instruments that robustly predict lower circulating IL-6 and hs-CRP. Second, the iPSC-macrophage platform needs to deliver quantitative readouts: does everolimus or *RPTOR* knockdown increase TFEB/TFE3 nuclear localization, and does that reduction in IL-6 disappear under *ATG7* knockout? Third, multivariable MR conditioning on *RICTOR* and *IGF1R* must confirm that any genetic signal is specific to mTORC1 and not an artifact of nutrient-sensing network pleiotropy. Until these three gates are passed, expansion to full cytokine panels, organismal lifespan data, or other hallmarks of aging remains appropriately deprioritized.\n\nOverall, the direction is scientifically coherent and aligns with established geroscience paradigms, but the honest assessment is that we remain at the starting line. The decision to scope narrowly and accept a zero-finding tick reflects methodological discipline: we are refusing to assert a causal edge until human genetics, cellular mechanism, and pathway specificity converge. We will continue to scan the literature and await empirical outputs before upgrading confidence.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}
Inference calls7